Abstract
The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.
| Original language | English (US) |
|---|---|
| Pages (from-to) | e601-e612 |
| Journal | The Lancet Haematology |
| Volume | 7 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2020 |
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era : recommendations from a panel of international experts. / Zeidan, Amer M.; Boddu, Prajwal C.; Patnaik, Mrinal M.; Bewersdorf, Jan Philipp; Stahl, Maximilian; Rampal, Raajit K.; Shallis, Rory; Steensma, David P.; Savona, Michael R.; Sekeres, Mikkael A.; Roboz, Gail J.; DeAngelo, Daniel J.; Schuh, Andre C.; Padron, Eric; Zeidner, Joshua F.; Walter, Roland B.; Onida, Francesco; Fathi, Amir; DeZern, Amy; Hobbs, Gabriela; Stein, Eytan M.; Vyas, Paresh; Wei, Andrew H.; Bowen, David T.; Montesinos, Pau; Griffiths, Elizabeth A.; Verma, Amit K.; Keyzner, Alla; Bar-Natan, Michal; Navada, Shyamala C.; Kremyanskaya, Marina; Goldberg, Aaron D.; Al-Kali, Aref; Heaney, Mark L.; Nazha, Aziz; Salman, Huda; Luger, Selina; Pratz, Keith W.; Konig, Heiko; Komrokji, Rami; Deininger, Michael; Cirici, Blanca Xicoy; Bhatt, Vijaya Raj; Silverman, Lewis R.; Erba, Harry P.; Fenaux, Pierre; Platzbecker, Uwe; Santini, Valeria; Wang, Eunice S.; Tallman, Martin S.; Stone, Richard M.; Mascarenhas, John.
In: The Lancet Haematology, Vol. 7, No. 8, 08.2020, p. e601-e612.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era
T2 - recommendations from a panel of international experts
AU - Zeidan, Amer M.
AU - Boddu, Prajwal C.
AU - Patnaik, Mrinal M.
AU - Bewersdorf, Jan Philipp
AU - Stahl, Maximilian
AU - Rampal, Raajit K.
AU - Shallis, Rory
AU - Steensma, David P.
AU - Savona, Michael R.
AU - Sekeres, Mikkael A.
AU - Roboz, Gail J.
AU - DeAngelo, Daniel J.
AU - Schuh, Andre C.
AU - Padron, Eric
AU - Zeidner, Joshua F.
AU - Walter, Roland B.
AU - Onida, Francesco
AU - Fathi, Amir
AU - DeZern, Amy
AU - Hobbs, Gabriela
AU - Stein, Eytan M.
AU - Vyas, Paresh
AU - Wei, Andrew H.
AU - Bowen, David T.
AU - Montesinos, Pau
AU - Griffiths, Elizabeth A.
AU - Verma, Amit K.
AU - Keyzner, Alla
AU - Bar-Natan, Michal
AU - Navada, Shyamala C.
AU - Kremyanskaya, Marina
AU - Goldberg, Aaron D.
AU - Al-Kali, Aref
AU - Heaney, Mark L.
AU - Nazha, Aziz
AU - Salman, Huda
AU - Luger, Selina
AU - Pratz, Keith W.
AU - Konig, Heiko
AU - Komrokji, Rami
AU - Deininger, Michael
AU - Cirici, Blanca Xicoy
AU - Bhatt, Vijaya Raj
AU - Silverman, Lewis R.
AU - Erba, Harry P.
AU - Fenaux, Pierre
AU - Platzbecker, Uwe
AU - Santini, Valeria
AU - Wang, Eunice S.
AU - Tallman, Martin S.
AU - Stone, Richard M.
AU - Mascarenhas, John
N1 - Funding Information: AMZ received research funding (institutional) from Celgene (Bristol Myers Squibb), Abbvie, Astex, Pfizer, Medimmune (AstraZeneca), Boehringer-Ingelheim, Trovagene, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics; participated in advisory boards or had a consultancy with, and received honoraria from, AbbVie, Otsuka, Pfizer, Celgene (Bristol Myers Squibb), Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis, Amgen, Janssen, Epizyme, and Tyme; served on steering and independent data review committees for clinical trials for Novartis and Janssen; and received travel support for meetings from Pfizer, Novartis, and Trovagene. MMP is on the advisory board for Stem Line Pharmaceuticals. RKR has received consulting fees from Constellation, Incyte, Celgene, Promedior, CTI, Jazz Pharmaceuticals, Blueprint, and Stemline; and research funding from Incyte, Constellation, and Stemline. MRS is on the advisory boards for Abbvie, Bristol Myers Squibb, Celgene, Sierra Oncology, Ryvu, Takeda, and TG Therapeutics; is a consultant for Karyopharm and Ryvu; and receives grants and research support from Astex, Incyte, and TG Therapeutics, royalties from Bohringer-Ingelheimand, and equity from Karyopharm. MAS is on the advisory boards for Bristol Myers Squibb and Takeda (Millenium). RMS has served on independent data safety monitoring committees for trials supported by Celgene, Takeda, and Argenix; has consulted for AbbVie, Actinium, Agios, Amgen, Arog, Astellas, AstraZeneca, Biolinerx, Celgene, Daiichi Sankyo, Fujifilm, Janssen, Juno, Macrogenics, Novartis, Ono, Orsenix, Pfizer, Roche, Stemline, Sumitomo, Takeda, and Trovagene; and has received research support (to the institution) for clinical trials sponsored by AbbVie, Agios, Arog, and Novartis. JFZ has received honoraria from AbbVie, Agios, AsystBio Laboratories, Celgene, Daiichi Sankyo, Genentech, Pfizer, and Takeda; is a consultant and is on advisory boards for, or has received research funding from AROG Pharmaceuticals, Celgene, Forty Seven, Merck, Takeda, and Tolero. AF is consulting for Celgene (Bristol Myers Squibb), Novartis, Agios, Astellas, Pfizer, Takeda, Amgen, Daiichi Sankyo, Kite, Trovagene, Forty Seven, NewLink Genetics, and Abbvie; and receives clinical trial support from Celgene and Agios. EMS has served on advisory boards for Abbvie, Agios, Amgen, Astellas, Celgene, Daiichi Sankyo, Genentech, Novartis, and Seattle Genetics, and has received research support (to his institution) from Agios, Amgen, Bayer, Biotheryx, Celgene, Syndax, and Syros. GH has served on advisory boards for SAB Incyte, Agios, Jazz, Bristol Myers Squibb, and Celgene; has received research support from Bayer, Merck, Incyte, and Constellation; and has received grants from ASH-AMFDP, K-12 CA087723, and the Sanchez Ferguson Award. GJR has served on independent data safety monitoring committees for trials supported by AbbVie, Actinium, Agios, Amphivena, Argenx, Array Biopharma, Astex, Astellas, AstraZeneca, Bayer, Celgene, Celltrion, Daiichi Sankyo, Eisai, Epizyme, Helsinn, Janssen, Jasper Therapeutics, Jazz, and MEI Pharma; has served as chair for independent data monitoring committees for Novartis, Orsenix, Otsuka, Pfizer, Roche (Genentech), Sandoz, Takeda, IRC Chair, and Trovagene; and receives research support from Cellectis. ACS has acted as a consultant or served on advisory boards for, or received research support from, AbbVie, Agios, Amgen, Astellas, Celgene (Bristol Myers Squibb), GlycoMimetics, Jazz, Novartis, Phebra, Pfizer, and Teva. EP has received research funding from Bristol Myers Squibb, Kura, and Incyte, and has received honorarium from Novartis, Blueprint, and Stemline. ESW served on advisory boards or provided consulting for Abbvie, Astellas, Daiichi Sankyo, Dava Oncology (Arog), Genentech, Jazz, Kite Pharmaceuticals, Kura Oncology, Macrogenics, Pfizer, PTC Therapeutics, and Stemline; served on independent data review committees for clinical trials for Abbvie, Genentech, and Rafael Pharmaceuticals; and serves as a speaker for Stemline and Pfizer. MLH received research funding (institutional) from Blueprint, Celgene (Bristol Myers Squibb), CTI Biopharma, Deciphera, Novartis, Phizer, Roche (Genentech), and Sierra Oncology, and participated in advisory boards or had a consultancy with, and received honoraria from, Abbvie, Blueprint, CTI Biopharma, Incyte, Novartis, and Partner Therapeutics. VRB reports receiving consulting fees from Agios, Incyte, Partner Therapeutics, Omeros, Takeda, and Abbvie; research funding from Incyte, Jazz, Tolero Pharmaceuticals, and the National Marrow Donor Program; and funding support for a trial from Oncoceutics. HK served on advisory boards or provided consulting for Agios, Novartis, and Pfizer. SL reports grants to her institution from Biosight, Celgene, Hoffman La Roche, Kura, and Onconova; and honoraria from Acceleron, Agios, Daichii-Sankyo, Bristol Myers Squibb, and Jazz. KWP receives institutional research funding from AbbVie, Agios, Daiichi Sankyo, and Millennium; and is an advisory board member for AbbVie, Astellas, Celgene, and Boston BioMedical. RK serves on the speaker bureau for JAZZ, Agios, and Abbvie; and served on advisory boards or provided consulting for JAZZ, Agios, Abbvie, Celgene, and Acceleron. PF receives research support from Celgene (Bristol Myers Squibb), Janssen, Abbvie, Agios, and Novartis. UP consulted, attended an advisory board, or received honoraria from Amgen, Celgene, Abbvie, Novartis, and Takeda. EAG has received institutional research funding from Genentech, Astex (Otsuka), Apellis, Celldex Therapeutics, and Celgene (Bristol Myers Squibb); and has participated in advisory boards for AbbVie, Astex (Otsuka), Celgene (Bristol Myers Squibb), and Alexion Pharmaceuticals. AN has received honoraria from Mount Sinai Hospital and the University of Toronto; research support from Jazz Pharmaceutical, Meriani, Raffael pharmaceutical, PTC Therapeutics, Tolero Pharmaceuticals, Millennium Pharmaceuticals, Syros Pharmaceuticals, Pfizer, Seattle Genetics, Diiachi Sanykyo, Celgene, Imago BioScience, Sierra Oncology, Geron Corporation, Samumed, Clear Creek Bio, Forty Seven, Abbvie, MacroGenics, Glycomimetics, CTI BoiPharma, Incyte Corporation, Aprea Therapeutics, Kura Oncology, and Selvitape; is on the speaker bureau for Incyte Corporation and Novartis; is part of a data monitoring committee for MEI Pharma; has served on the advisory board or has consulted for Karyopharma, Abbvie, and Daiichi Sankyo; and is a consultant for Guidepoint, the American Society of Hematology, the Physicians' Education Resource, Medicom WorldWide, and Hemedicus. AA-K received research support to their institution from Novartis, Onconova, Celgene (Bristol Myers Squibb), Astex, Medimmune (AstraZeneca), Aprea, Daiichi Sankyp, and H3B Biomedicine. ADG served on advisory boards for, or was a consultant for, AbbVie, Aptose, Celgene, Daiichi Sanyko, and Genentech; received institutional research funding from AbbVie, A.D.C Therapeutics, Aprea, AROG Pharmaceuticals, Daiichi Sanyko, and Pfizer; and received honoraria from Dava Oncology. JM received institutional research funding from Incyte, CTI Biopharma, Novartis, Merck, Roche, Kartos, Promedior, Janssen, Merus, and Arog and consulting honoraria from Celgene, Prelude, Galecto, Roche, Constellation, and Incyte. All authors with competing interests declare that none of these relationships were related to the development of this manuscript. All other authors report no competing interests. Funding Information: The experts on this panel are haematologists and oncologists who specialise in leukaemia and transplant care, and discussions were held through virtual, online meetings. No external support was received for this Viewpoint. Amer M Zeidan is a Leukaemia and Lymphoma Society scholar in clinical research and is also supported by a National Cancer Institute's Cancer Clinical Investigator Team Leadership Award. Research reported in this publication was in part financially supported by the National Cancer Institute of the National Institutes of Health under award number P30 CA016359. The content of this Viewpoint is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. This publication was not funded by the National Institutes of Health. The funder of the publication had no role in the writing of the report. The corresponding author had final responsibility for the decision to submit for publication. Publisher Copyright: © 2020 Elsevier Ltd
PY - 2020/8
Y1 - 2020/8
N2 - The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.
AB - The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.
UR - http://www.scopus.com/inward/record.url?scp=85087508878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087508878&partnerID=8YFLogxK
U2 - 10.1016/S2352-3026(20)30205-2
DO - 10.1016/S2352-3026(20)30205-2
M3 - Review article
C2 - 32563283
AN - SCOPUS:85087508878
VL - 7
SP - e601-e612
JO - The Lancet Haematology
JF - The Lancet Haematology
SN - 2352-3026
IS - 8
ER -